web analytics
1.3 C
Munich
Sunday, November 27, 2022

Everyone Loves Cocrystal Pharma Inc (OTCBB:COCP)

Cocrystal Pharma Inc (OTCBB:COCP) continues to trade big volume over $1 maintaining itself among the volume leaders on the bb’s. The stock recently made a big move up off its $0.25 base to highs over $1.50 a share.

All the excitement on COCP is about billionaire Dr. Phillip Frost 100 million shares stake in the Company; the man is a self-made billionaire with a keen eye on bb’s with big futures and he regularly receives nation media attention from the likes of Bloomberg, CNBC and Barron’s. For more on Dr Phillip Frost check out MBVX and DRNE

Cocrystal Pharma Inc (OTCBB:COCP) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company owns technology based on the work of their Chief Scientific Officer, Dr. Roger Kornberg and Dr. Raymond Schinazi.

Dr. Kornberg was awarded the 2006 Nobel Prize for Chemistry for his work to actually visualize a replication enzyme called RNA polymerase in action. Using techniques called protein cocrystallization and X-ray crystallography, Dr. Kornberg and his colleagues generated a three dimensional picture similar to the one at left of RNA being transcribed by RNA polymerase. Dr. Schinazi is a world class expert in discovering novel nucleoside therapeutics. He founded or co-founded successful antiviral companies including Triangle Pharmaceuticals Inc., Idenix Pharmaceuticals Inc. and Pharmasset, Inc.

Cocrystal Pharma is leveraging its expertise in these methods to identify and develop new antiviral compounds. Using these methods, COCP scientists are able to directly visualize how viral replication enzymes work, to identify key parts of these enzymes to target, to design compounds to block the function of these enzymes, thereby preventing viruses from replicating and to discover novel nucleosides and other compounds which inhibit viral replication.

COCP drug pipeline currently comprises five drug candidates for hepatitis C, influenza, norovirus, the common cold and dengue fever. These five viruses kill a combined 6 million people annually. All five of Cocrystal Discovery’s drugs would be orally administered in the form of once-a-day pills, making them easily distributable around the world- especially valuable in third world areas without consistent refrigeration in healthcare distribution.

To Find out the inside Scoop on COCP  Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The Company got into the Ebola frenzy in October of last year when they announced they had developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product. According to Cocrystal Chief Scientist, Dr. Roger Kornberg, “We are very excited to have cloned the gene, purified and characterized its product, and integrated the gene product into our high-throughput platform. We believe we are the first group to have developed a novel screening methodology that can accurately identify inhibitors, which are potential drug candidates.”

On March 12 COCP announced that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board.

Mr. Meckler has over 25 years of experience in life science companies including 17 years at Pfizer Inc. in a variety of positions, including Manufacturing, Systems, Market Research and Corporate Finance. Mr. Meckler most recently was the Principal Executive Officer of QLT Inc., an ophthalmic orphan drug company located in Vancouver, British Columbia.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $124 million market valuation COCP has transformed itself in recent months to one of the top most traded stocks on the entire bb stock exchange. The Company has some very big names behind it and looks to be making some big moves. Clearly management and Dr. Phillip Frost know a lot more than anyone else and they are busy buying heavily here. Talk about a huge vote of confidence. We will be updating on COCP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with COCP.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COCP either long or short and we have not been compensated for this article.

More articles

3 COMMENTS

  1. This is old news. What have you found that is new news lately. The stock has dropped from its high in late March (3 months ago — a full quarter now) by more than a quarter of its value. Sounds to me like it is being hyped up to keep it from further price erosion. Hell, if it keeps up at this rate the stock will be worthless by the end of the first quarter of 2016.

    • Ok, now it is July 15, that’s 1/2 a month after the rosy picture that everyone loves Cocrystal and the shares have dropped another 20%. Right now it is at .925 per share. At this rate the stock will be worthless by October 2015 — that’s 5 months earlier than I speculated last time.

    • Well, lets do a price check here. It is now the end of August. Price right now is .75 and the erosion continues. It may not be October that the stock becomes worthless, but clearly it is on the way down and sinking. I see a new article from Alex Ryan today in MicroCap Daily with a little more pessimism than earlier articles. This is good. There has been a drop of 50% in the stock value and we now have a pundit indicating a little concern.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.